QQ客服 官方微博 反馈留言

	Enzyme Responsive Nanoparticles Co-Deliver Doxorubicin and Decitabine to Reverse Breast Cancer Multi-Drug Resistance [酶响应纳米粒子共输送地西他滨阿霉素逆转乳腺癌多药耐药]
	Liu Y.-Y.; Wang R.-M.
刊名	Chinese Journal of Pharmaceutical Biotechnology
	2018
卷号	25期号:4页码:288-293
关键词	Breast cancer Decitabine Doxorubicin Matrix metalloproteinase Multi-drug resistance,Nanodrug
DOI	10.19526/j.cnki.1005-8915.20180402
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4580290
专题	山东大学
作者单位	1.The No.2 Hospital of Shandong University, Department of Pharmacy, Jinan, 250000, China 2.The No.2 Hospital of Shandong Univers
推荐引用方式 GB/T 7714	Liu Y.-Y.,Wang R.-M.. Enzyme Responsive Nanoparticles Co-Deliver Doxorubicin and Decitabine to Reverse Breast Cancer Multi-Drug Resistance [酶响应纳米粒子共输送地西他滨阿霉素逆转乳腺癌多药耐药][J]. Chinese Journal of Pharmaceutical Biotechnology,2018,25(4):288-293.
APA	Liu Y.-Y.,&Wang R.-M..(2018).Enzyme Responsive Nanoparticles Co-Deliver Doxorubicin and Decitabine to Reverse Breast Cancer Multi-Drug Resistance [酶响应纳米粒子共输送地西他滨阿霉素逆转乳腺癌多药耐药].Chinese Journal of Pharmaceutical Biotechnology,25(4),288-293.
MLA	Liu Y.-Y.,et al."Enzyme Responsive Nanoparticles Co-Deliver Doxorubicin and Decitabine to Reverse Breast Cancer Multi-Drug Resistance [酶响应纳米粒子共输送地西他滨阿霉素逆转乳腺癌多药耐药]".Chinese Journal of Pharmaceutical Biotechnology 25.4(2018):288-293.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。